Journals / Medicine Science / 2014 / Cilt: 3 - Sayı: 4

The Relationship of the Peroxisome Proliferator Activated Receptor-Gamma 2 Exon 2 and Exon 6 Gene Polymorphism in Type 2 Diabetic Patients with and without Diabetic Foot Ulcers

Pages
1582–1594
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Genetic factors in the pathogenesis of diabetic foot may also show any changes in different populations.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We aims investigate Turkish type 2 diabetic patients with/without diabetic foot ulcers and healthy group and examined the contribution of the Pro12Ala exon 2 and C478T exon 6 of the PPARgamma gene polymorphisms to the development of diabetic foot ulcers.
📊
Key Findings & Data:The PPARgamma genotypes were determined prospectively in 50 patients with diabetic foot ulcers and 50 without diabetic foot ulcers and a control group of 50 healthy individuals.
💡
Conclusion & Impact:Genetic factors in the pathogenesis of diabetic foot may also show any changes in different populations.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

We aims investigate Turkish type 2 diabetic patients with/without diabetic foot ulcers and healthy group and examined the contribution of the Pro12Ala exon 2 and C478T exon 6 of the PPARgamma gene polymorphisms to the development of diabetic foot ulcers. The PPARgamma genotypes were determined prospectively in 50 patients with diabetic foot ulcers and 50 without diabetic foot ulcers and a control group of 50 healthy individuals. Genotyping of the Pro12Ala exon 2 and C478T exon 6 of the PPAR-gamma gene polymorphisms for all individuals was performed by PCR-RFLP method. The genotype exon 2 and exon 6 distribution did not differ between the control group and the type 2 diabetes mellitus patients (with and without diabetic foot) (P>0.05). The frequency of the polymorphic G allele in exon 2 was no similar for the groups (6% and 1%, respectively) (p<0.05). The frequency of the polymorphic T allele in exon 6 was similar for the groups (p>0.05). The evaluation of exon 2 and exon 6, genotype and haplotype did not show statistically significant difference between the patient diabetic foot and without diabetic foot (p>0.05). The Pro12Ala exon 2 and C478T exon 6 of the PPARgamma gene polymorphisms are not an independent risk factor for diabetic foot in Turkish type 2 diabetes mellitus patients. Genetic factors in the pathogenesis of diabetic foot may also show any changes in different populations.

🔖

Cite This Article

ERDOĞAN, M., EROĞLU, Z., SOLMAZ, S., GANİDAGLİ, S., TETİK, A., CANATAROĞLU, A. (2014). The Relationship of the Peroxisome Proliferator Activated Receptor-Gamma 2 Exon 2 and Exon 6 Gene Polymorphism in Type 2 Diabetic Patients with and without Diabetic Foot Ulcers. Medicine Science, Cilt: 3 - Sayı: 4, 1582–1594. https://ajindex.com/articles/277976

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Richard JL, Schuldiner S. Epidemiology of diabetic foot problems. Rev Med Interne. 2008;29 Suppl 2:S222-30
  2. Malgrange D. Physiopathology of the diabetic foot. Rev Med Interne. 2008;29 Suppl 2:S231-7
  3. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: The oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord. 2008;9(4):301-14
  4. Martini J. Diabetic foot: detection and prevention. Rev Med Interne. 2008;29 Suppl 2:S260-3
  5. Got I. Peripheral vascular disease and diabetic foot. Rev Med Interne. 2008;29 Suppl 2: S249-59
  6. Ricco JB, Thanh Phong L, Schneider F, Illuminati G, Belmonte R, Valagier A, Régnault De La Mothe G. The diabetic foot: a review. J Cardiovasc Surg (Torino). 2013;54(6):755-62
  7. Senneville E. Infection and diabetic foot. Rev Med Interne. 2008;29 Suppl 2: S243-8
  8. Ray DM, Spinelli SL, O'Brien JJ, Blumberg N, Phipps RP. Platelets as a novel target for PPARgamma ligands: implications for inflammation, diabetes, and cardiovascular disease. BioDrugs. 2006;20(4):231-41
  9. Dumasia R, Eagle KA, Kline-Rogers E, May N, Cho L, Mukherjee D. Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5(5):377-86
  10. Deray G, Izzedine H, Launay-Vacher V, Bagnis C. [Kidney and glitazones] Ann Endocrinol (Paris). 2005;66(2 Pt 2):1S81-90
  11. Nicholas SB, Kawano Y, Wakino S, Collins AR, Hsueh WA. Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. Hypertension. 2001;37(2 Pt 2):722-7
  12. Stefanski A, Majkowska L, Ciechanowicz A, Frankow M, Safranow K, Parczewski M, Pilarska K. Lack of association between the Pro12Ala polymorphism in PPAR-gamma2 gene and body weight changes, insulin resistance and chronic diabetic complications in obese patients with type 2 diabetes. Arch Med Res. 2006;37(6):736-43
  13. Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Harkless LB, Boulton AJ. A Comparison of Two Diabetic Foot Ulcer Classification Systems: The Wagner and The University of Texas Wound Classification Systems. Diabetes Care. 2001;24(1):84-8
  14. Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, Edmonds M, Holstein P, Jirkovska A, Mauricio D, Ragnarson Tennvall G, Reike H, Spraul M, Uccioli L, Urbancic V, Van Acker K, van Baal J, van Merode F, Schaper N. High Prevalence of Ischemia, Infection and Serious Comorbidity in Patients with Diabetic F